SUBRETINAL NEOVASCULARIZATION IN MACULAR TELANGIECTASIA TYPE 2: OPTICAL COHERENCE TOMOGRAPHIC ANGIOGRAPHY AND TREATMENT RESPONSE.
OBJECTIVE
To report the optical coherence tomographic angiography findings and response to treatment in a case of macular telangiectasia Type 2 with subretinal neovascularization.


METHODS
Case report.


RESULTS
A 64-year-old man with macular telangiectasia Type 2 developed subretinal neovascularization, which was imaged on optical coherence tomographic angiography. He was treated with intravitreal aflibercept, and there was a remarkable reduction of flow in the subretinal neovascular network on optical coherence tomographic angiography.


CONCLUSIONS
Optical coherence tomographic angiography provides detailed information on the retinal microvasculature and subretinal neovascularization in macular telangiectasia Type 2. It can be used to assess response to treatment.
*Department of Ophthalmology, Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles, California; †Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore; and ‡Doheny Eye Institute, David Geffen School of Medicine, UCLA, Los Angeles, California.
Gavin S
GS
Tan
Laura
L
Kuehlewein
Srinivas R
SR
Sadda
David
D
Sarraf
Steven D
SD
Schwartz
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D005451:Fluorescein Angiography; D006801:Humans; D008266:Macula Lutea / Q000473:pathology; D008297:Male; D008875:Middle Aged; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D015861:Retinal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D058456:Retinal Telangiectasis / Q000150:complications* / Q000188:drug therapy; D041623:Tomography, Optical Coherence
D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor